Loading…
← CockpitCompetitor Analysis › SUNPHARMA.NS Sun Pharmaceutical IndustriesOpen in the cockpit ↗

Sun Pharmaceutical IndustriesSUNPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

India's largest pharmaceutical company, making generic and specialty drugs sold in over 100 countries.

≈ India's Teva Pharmaceutical, with a growing US specialty armMomentum neutral 59
Mkt cap
$48.0B
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$44.6M
20-day average traded
Fwd P/E
36.0×
forward earnings
ROIC−WACC
+4.7 pp
WACC 13.3%
Hurdle
+17 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · INR₹1,872
1D+0.1%
1W-1.6%
1M+7.4%
3M-0.2%
6M-0.6%
YTD+8.8%
1Y+8.1%
ATR %2.2%
Beta0.44
52w lowhigh8.6% off high

What Sun Pharmaceutical Industries does

India's largest pharmaceutical company, making generic and specialty drugs sold in over 100 countries.

Earns from branded generics sold to Indian doctors and pharmacies, its home business, and from the US, where it sells generics and, increasingly, its own specialty brands; India and the US are its two biggest markets. The Shanghvi family controls it. The 2015 purchase of Ranbaxy and later full ownership of Israel's Taro Pharmaceutical widened its range.

In one line: India's Teva Pharmaceutical, with a growing US specialty arm.

Products and services

  • Generic pharmaceuticals
  • Specialty products (Ilumya, Winlevi)
  • Active pharmaceutical ingredients (API)
  • Consumer healthcare (India OTC)

Customers

  • US and global generic-drug distributors/pharmacies
  • Hospitals and physicians (specialty)
  • Indian domestic pharmacy trade

Where it sits in the supply chain

  • Pharmaceuticals
  • Generic & specialty drug manufacturing
  • Generics (US, India, emerging markets)…

What could go right

  • Growing specialty-drug revenue mix
  • US generic-market share gains

What could go wrong

  • US generic-pricing pressure
  • Regulatory/FDA plant-inspection risk

Moat: narrow (scale, IP / patents, regulatory licence). Global manufacturing scale plus a growing patented specialty pipeline differentiate it from pure generic peers.

Headquarters: Mumbai, India · Founded: 1983 · Employees: 28,925

Named competitors

Sun Pharmaceutical Industries at a glance

Size Sun Pharmaceutical Industries (SUNPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $48.0B, the 14th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,872 on 18 Nov 2026.

Performance Over six months the shares fell 0.6%, against +16.9% for the median peer and +3.8% for the India market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 12.1% over the last twelve months (peer median +13.6%); the operating margin is 23.2% (peer median 19.0%).

Valuation It trades at 36.0× forward earnings against a peer median of 19.0× (5th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.7 points above its cost of capital (13.3% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 115SUNPHARMA.NS 100
Six months, rebased to 100: Sun Pharmaceutical Industries against the median of its 20 peers (local-currency closes).

Sun Pharmaceutical Industries financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹616B₹583B₹522B₹479B₹439B
Revenue growth—+12%+9%+9%—
Gross profit₹345B₹310B₹284B₹241B₹200B
EBITDA₹173B₹174B₹150B₹121B₹116B
Net income₹110B₹115B₹109B₹95.8B₹84.7B
Free cash flown/a₹92.4B₹126B₹104B₹32.2B
Capital expendituren/a₹36.1B₹21.3B₹22.0B₹20.9B
Total debt₹32.4B₹46.3B₹23.6B₹32.7B₹68.9B

Quarterly statements and history in the cockpit →

Sun Pharmaceutical Industries competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%600276688235GALDSDZ4578HLNRPRXBAYNBIIB2359ZTS4502MRK45034568DIVISLAB4519ROIVINSM3692SUNPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Sun Pharmaceutical Industries is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×40×60×600276688235GALDSDZ4578HLNRPRXBAYN2359ZTS450245034568DIVISLAB45193692SUNPHARMA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sun Pharmaceutical Industries is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%600276688235GALDSDZ4578HLNRPRX2359ZTS4503DIVISLAB3692SUNPHARMA.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sun Pharmaceutical Industries is the large dot.

Sun Pharmaceutical Industries competitors and peer comparison

Head to head with its named competitors (SUNPHARMA.NS vs DRREDDY.NS vs CIPLA.NS vs TEVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%32.0×30.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%

How Sun Pharmaceutical Industries compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sun Pharmaceutical Industries against its 20 peers (data as of 18 Nov 2026)
MeasureSUNPHARMA.NSPeer medianRank in peer set
1-month return+7.4%+6.3%9th highest of 21
6-month return-0.6%+16.9%4th lowest of 21
Distance from 52-week high-8.6%-7.7%11th highest of 21
Revenue growth (TTM)+12.1%+13.6%11th highest of 21
Operating margin23.2%19.0%10th highest of 21
Forward P/E36.0×19.0×5th most expensive of 19
Growth the price implies (Req g, 7 yrs)28.7%7.6%2nd most demanding of 18
Growth delivered (Del g)+11.7%+7.2%4th highest of 18
Hurdle (Req g minus delivered)+17.0 pp-2.9 pp2nd most demanding of 18
ROIC minus cost of capital+4.7 pp+4.6 pp11th highest of 21
EV / EBITDA24.2×13.8×5th most expensive of 17
Net debt / EBITDA-1.8×1.3×3rd least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%

Questions

Who are Sun Pharmaceutical Industries's main competitors?
Named competitors: Dr. Reddy's Laboratories (DRREDDY.NS), Cipla (CIPLA.NS), Teva Pharmaceutical Industries (TEVA), Viatris (VTRS). The cockpit's measured peer set (industry) also includes Jiangsu Hengrui Pharmaceuticals (600276.SS), BeOne Medicines (688235.SS), Galderma (GALD.SW), Sandoz (SDZ.SW), Otsuka Hldgs (4578.T), Haleon (HLN.L).
Is Sun Pharmaceutical Industries expensive compared with its peers?
On forward p/e it trades at 36.0× against a peer median of 19.0×, 5th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sun Pharmaceutical Industries stock performed?
Over six months to 18 Nov 2026 the shares returned -0.6% against +16.9% for the median peer; over one year +8.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.